Assessment of messenger RNA of β1→4-N-acetylgalactosaminyltransferase as a molecular marker for metastatic melanoma

Clinical Cancer Research

Volumn 4, Issue 2, 1998, Pages 411-418

  Kuo, Christine T ^a   Bostick, Peter J ^a   Irie, Reiko F ^a   Morton, Donald L ^a   Conrad, Andrew J ^b   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b National Genetics Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA; N ACETYLGALACTOSAMINYLTRANSFERASE;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CELL SURFACE; HUMAN; HUMAN CELL; IMMUNOGENICITY; MELANOMA; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SKIN METASTASIS;

ANTIGENS, NEOPLASM; BLOTTING, SOUTHERN; CARBOHYDRATE SEQUENCE; DISEASE PROGRESSION; G(M2) GANGLIOSIDE; GANGLIOSIDES; HUMANS; MELANOMA; MOLECULAR SEQUENCE DATA; N-ACETYLGALACTOSAMINYLTRANSFERASES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031913995     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Morton, D. L., Ravindranath, M. H., and Irie, R. F. Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. Prog. Brain Res., 101: 251-275, 1994.
2. Tsuchida, T., Saxton, R. E., Morton, D. L., and Irie, R. F. Gangliosides of human melanoma. J. Natl. Cancer Inst., 78: 45-54, 1987.
3. Tsuchida, T., Saxton, R. E., and Irie, R. F. Gangliosides of human melanoma: GM2 and tumorigenicity. J. Natl. Cancer Inst., 78: 55-60, 1987.
4. Tai, T., Paulson, J. C., Cahan, L. D., and Irie, R. F. Ganglioside GM2 as a human tumor antigen (OFA-I-1). Proc. Natl. Acad. Sci. USA, 80: 5392-5396, 1983.
5. Cahan, L. D., Irie, R. F., Singh, R., Cassodenti, A., and Paulson, J. C. Identification of a human neuroectodermal tumor antigen (OFA-I-2) as ganglioside GD2. Proc. Natl. Acad. Sci. USA, 79: 7629-7633, 1982.
6. Gambia, J. M., Yu, R. K., Macala, L. J., Kirkwood, J. M., and Varga, J. M. Gangliosides of normal and neoplastic human melanocytes. Biochem. Biophys. Res. Commun., 120: 500-504, 1984.
7. Hoon, D. S. B., Okun, E., Neuwirth, H., Morton, D. L., and Irie, R. F. Aberrant expression of gangliosides in human renal cell carcinomas. J. Urol., 150: 2013-2018, 1993.
8. Schulz, G., Cheresh, D. A., Varki, N. M., Yu, A., Staffileno, L. K., and Reisfeld, R. A. Detection of ganglioside GD2 in tumor tissues and sera of neuroblastoma patients. Cancer Res., 44: 5914-5920, 1984.
9. Haqing, M., Avrova, N., Mansson, J. E., Molin, K., and Svennerholm, L. Gangliosides and neutral glycosphingolipids of normal tissue and oat cell carcinoma of human lung. Biochem. Biophys. Acta, 878: 360-370, 1986.
10. tax. Proc. Natl. Acad. Sci. USA, 90: 1972-1976, 1993.
11. Ruan, S., and Lloyd, K. O. Glycosylation pathways in the biosynthesis of gangliosides in melanoma and neuroblastoma cells: relative glycosyltransferase levels determine ganglioside patterns. Cancer Res., 52: 5725-5731, 1992.
12. Vrionis, F. D., Wikstrand, C. J., Fredman, P., Mansson, J. E., Svennerholm, L., and Bigner, D. D. Five new epitope-defined monoclonal antibodies reactive with GM2 and human glioma and medulloblastoma cell lines. Cancer Res., 49: 6645-6651, 1989.
13. Yuyama, Y., Dohi, T., Morita, H., Furukawa, K., and Oshima, M. Enhanced expression of GM2/GD2 synthase mRNA in human gastrointestinal cancer. Cancer (Phila.), 75: 1273-1280, 1995.
14. Tai, T., Cahan, L. D., Tsuchida, T., Saxton, R. E., Irie, R. F., and Morton, D. L. Immunogenicity of melanoma-associated gangliosides in cancer patients. Int. J. Cancer, 35: 607-612, 1985.
15. Livingston, P. O., Wong, G. Y. C., Adluri, S., Tao, Y., Padavan, M., Parente, R., Hanlon, C., Calves, M. J., Helling, F., Ritter, G., Oettgen, H. F., and Old, L. J. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol., 12: 1036-1044, 1994.
16. Hoon, D. S. B., Ando, I., Sviland, G., Tsuchida, T., Okun, E., Morton, D. L., and Irie, R. F. Ganglioside GM2 expression on human melanoma cells correlates with sensitivity to lymphokine-activated killer cells. Int. J. Cancer, 43: 857-862, 1989.
17. Jones, P. C., Sze, L. L., Liu, P. Y., Morton, D. L., and Irie, R. F. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal antigen. J. Natl. Cancer Inst., 66: 249-254, 1981.
18. Irie, R. F., Matsuki, T., and Morton, D. L. Human monoclonal antibody to ganglioside GM2 for melanoma treatment. Lancet, 1: 786-787, 1989.
19. Irie, R. F., and Morton, D. L. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc. Natl. Acad. Sci. USA, 83: 8694-8698, 1986.
20. Pohlentz, G., Klein, D., Schwarzmann, G., Schmitz, D., and Sandhoff, K. Both GA2, GM2, and GD2 synthases and GM1b, GD1a, and GT1b synthases arc single enzymes in Golgi vesicles from rat liver. Proc. Natl. Acad. Sci. USA, 85: 7044-7048, 1988.
21. Nagata, Y., Yamashiro, S., Yodoi, J., Lloyd, K. O., Shiku, H., and Furukawa, K. Expression cloning of β1,4-N-acetylgalactosaminyltransferase cDNAs that determine the expression of GM2 and GD2 gangliosides. J. Biol. Chem., 267: 12082-12089, 1992.
22. Yamashiro, S., Ruan, S., Furukawa, K., Tai, T., Lloyd, K. O., Shiku, H., and Furukawa, K. Genetic and enzymatic basis for the differential expression of GM2 and GD2 gangliosides in human cancer cell lines. Cancer Res., 53: 5395-5400, 1993.
23. Hoon, D. S. B., Wang, Y., Dale, P. S., Conrad, A. J., Schmid, P., Garrison, D., Kuo, C., Foshag, L. J., Nizze, A. J., and Morton, D. L. Detection of occult melanoma cells in blood with a multiple-marker polymerase chain reaction assay. J. Clin. Oncol., 13: 2109-2116, 1995.
24. Doi, F., Chi, D. D. J., Charuworn, B. B., Conrad, A. J., Russell, J., Morton, D. L., and Hoon, D. S. B. Detection of β-human chorionic gonadotropin mRNA as a marker for cutaneous malignant melanoma. Int. J. Cancer, 65: 454-459, 1996.
25. Sarantou, T., Chi, D. D. J., Garrison, D. A., Conrad, A. J., Schmid, P., Morton, D. L., and Hoon, D. S. B. Melanoma-associated antigens as messenger RNA detection markers for melanoma. Cancer Res., 57: 1371-1376, 1997.
26. Chi, D. D. J., Merchant, R. E., Rand, R., Conrad, A. J., Garrison, D., Turner, R., Morton, D. L., and Hoon, D. S. B. Molecular Detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am. J. Pathol., 150: 2143-2152, 1997.
27. Tsuchida, T., Saxton, R. E., Morton, D. L., and Irie, R. F. Gangliosides of human melanoma. Cancer (Phila.), 63: 1166-1174, 1989.
28. M3 that reacts to human cancer. Cancer Res., 53: 5244-5250, 1993.
29. Hoon, D. S. B., Kaback, M. M., Lim-Steele, J., Tsuchida, T., Morton, D. L., and Irie, R. F. Ganglioside GM2 levels in human melanoma cells: inverse correlation with lysosomal β-hexosaminidase A activity. Biochem. Int., 27: 343-352, 1992.
30. Dohi, T., Ohta, S., Hanai, N., Yamaguchi, K., and Oshima, M. Sialylpentaosylceramide detected with anti-GM2 monoclonal antibody. Structural characterization and complementary expression with GM2 in gastric cancer and normal gastric mucosa. J. Biol. Chem., 265: 7880-7885, 1990.
31. Dohi, T., Yuyama, Y., Natori, Y., Smith, P. L., Lowe, J. B., and Oshima, M. Detection of N-acetylgalactosaminyltransferase mRNA which determines expression of Sda blood group carbohydrate structure in human gastrointestinal mucosa and cancer. Int. J. Cancer. 67: 626-631, 1996.
32. Malagolini, N., Dall'Olio, F., Di Stefano, G., Minni, F., Marrano, D., and Serafini-Cessi, F. Expression of UDP-GalNAc:NeuAc alpha 2,3Galβ-Rβ1,4(GalNAc to Gal) N-acetylgalactosaminyltransferase involved in the synthesis of Sda antigen in human large intestine and colorectal carcinomas. Cancer Res., 49: 6466-6470, 1989.
33. Lloyd, K. O., Gordon, C. M., Thampoe, I. J., and DiBenedetto, C. Cell surface accessibility of individual gangliosides in malignant melanoma cells to antibodies is influenced by the total ganglioside composition of the cells. Cancer Res., 52: 4948-4953, 1992.
34. Morton, D. L., Wong, J. H., Kirkwood, J. M., and Parker, R. G. Malignant Melanoma. Chapter XXXIV. In: J. F. Holland et al. (eds.), Cancer Medicine, Ed. 3, pp. 1793-1824. Philadelphia: Lea & Febiger, 1993.
35. Morton, D. L., Foshag, L. J., Hoon, D., Nizze, J. A., Famatiga, E., Wanek, L. A., Chang, C., Davtyan, D. G., Gupta, R. K., Elashoff, R., and Irie, R. F. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann. Surg., 216: 463-482, 1992.
36. Helling, F., Zhang, S., Shang, A., Adluri, S., Calves, M., Koganty, R., Longnecker, B. M., Yao, T-J., Oettgen, H. F., and Livingston, P. O. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res., 55: 2783-2788, 1995.
37. Reisfeld, R. A., Mueller, B. M., Handgretinger, R., Yu, A. L., and Gillies, S. D. Potential of genetically engineered anti-ganglioside GD2 antibodies for cancer immunotherapy. Prog. Brain Res., 101: 201-212, 1994.
38. Cheung, N-K. V., Cheung, I. Y., Canete, A., Yeh, S. J. Kushner, B., Bonilla, M. A., Heller, G., and Larson, S. M. Antibody response to murine anti-GD2 monoclonal antibodies: correlation with patient survival. Cancer Res., 54: 2228-2233, 1994.